Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07614477RecruitingPhase 2
Testing EVER001 for kidney protein-loss diseases
This study tests a new drug called EVER001 to see if it can reduce protein loss in urine and improve kidney function in patients with specific kidney diseases (FSGS, MCD, or IgAN). These are autoimmune kidney conditions that cause the kidneys to leak protein into the urine.
Beijing, Beijing MunicipalityAges 18–75 - NCT07614776RecruitingPhase 3
New Eye Injection Treatment for Age-Related Macular Degeneration
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
Fullerton, CaliforniaAges 50 years+ - NCT07614958RecruitingPhase 3
Testing a new cholesterol medicine against bempedoic acid
This study compares two new medicines—obicetrapib and bempedoic acid—to see which one better lowers cholesterol in people whose cholesterol remains high despite taking standard medications. If your cholesterol isn't controlled well enough with current drugs, this trial may help you access an experimental treatment.
Stockton-on-TeesAges 18 years+ - NCT07608432RecruitingPhase 3
Testing a New DMD Treatment Given Every 4 Weeks
This study tests whether a new medicine called zeleciment rostudirsen can help ambulatory (walking) males with Duchenne muscular dystrophy (DMD). The medicine is given as an intravenous infusion (through a vein) every 4 weeks and works by helping the body produce a protective muscle protein.
Hillsborough, North CarolinaAges 4–18 - NCT07608770RecruitingPhase 2
CBL-514 injection to reduce belly fat
This study tests whether CBL-514, an injection given under the skin, can safely reduce stubborn belly fat in people with normal to slightly elevated weight. Researchers will measure changes in abdominal fat using imaging and patient assessments.
South Yarra, VictoriaAges 18 years+ - NCT06278857RecruitingPhase 2
Dostarlimab for early-stage MMR deficient endometrial cancer
This trial tests the drug dostarlimab for patients with early-stage endometrial cancer that is MMR deficient. It aims to see if the treatment is safe and effective for those who want to preserve their uterus or cannot have surgery.
Sydney, New South WalesAges 18 years+ - NCT07595003RecruitingPhase 3
Testing a new medicine for gallbladder pain and discomfort
This study tests whether a medicine called 4-MUST can safely reduce pain and digestive symptoms caused by chronic gallbladder problems. You'll take tablets for several weeks while researchers track how well the medicine works and any side effects.
MoscowAges 18–70 - NCT07594158RecruitingPhase 3
ONO-2017 for Seizures in Japanese Children and Teens
This study tests a new seizure medication called ONO-2017 in Japanese children and teenagers (ages 2–17) who have a specific type of seizure called POS that hasn't been controlled by current medicines. The goal is to see if this new drug is safe and helps reduce these seizures.
FukuokaAges 2–17 - NCT07588672Recruiting
Allergy Blocker Spray for Seasonal Nasal Allergies
This trial tests whether PL-14, a new nasal spray, works better than saline spray at relieving seasonal allergy symptoms like sneezing, itching, and congestion. If it works well and is safe, it could offer patients a new way to manage allergies during pollen season.
Normal, IllinoisAges 18–75 - NCT07588438RecruitingPhase 4
Tirzepatide effectiveness and safety for diabetes and weight loss in Paraguay
This study tests how well and safely tirzepatide (a new injectable medication) works in real-world conditions for people with type 2 diabetes or obesity in Paraguay. The medication helps lower blood sugar and reduce weight.
AsunciónAges 18–70 - NCT07582432RecruitingPhase 3
Gamunex for Blood Cancer Patients With Low Antibodies
This trial tests whether Gamunex, an antibody replacement therapy, helps patients with chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin lymphoma who have low immunoglobulin (antibody) levels. The treatment may reduce infections and improve how well the body fights disease.
St. Petersburg, FloridaAges 18 years+ - NCT07575399RecruitingPhase 3
Switching to a New Weight-Loss Medication From Current GLP-1
This trial tests whether switching from your current GLP-1 medication (like Ozempic or Wegovy) to a new drug called maridebart cafraglutide works as well or better for weight management. You must have already lost at least 10% of your body weight on your current GLP-1 and be doing well with it.
Pelham, AlabamaAges 18–99 - NCT07570654RecruitingPhase 2/Phase 3
Testing COMP360 for post-traumatic stress disorder
This study tests whether COMP360, a new treatment, can help people with PTSD feel better and cope with their symptoms. The research team will measure how safe it is and how well it works over time.
Miami, FloridaAges 18 years+ - NCT06349980RecruitingPhase 2
Study of three drugs for liver cancer not yet treated
This trial is testing a combination of three drugs (HLX10, HLX04, and HLX53) to find the best dose and see if they help people with advanced liver cancer who have not had systemic treatment before. The goal is to shrink tumors and improve survival.
ShanghaiAges 18 years+ - NCT07557420RecruitingPhase 3
Ravulizumab for Neuromyelitis Optica Spectrum Disorder in Chinese Adults
This study tests a new medicine called ravulizumab (an infusion) to reduce relapses in people with neuromyelitis optica spectrum disorder (NMOSD), a rare condition affecting the optic nerve and spinal cord. The trial is specifically enrolling adults in China who have had recent disease activity.
BeijingAges 18–130 - NCT07551427RecruitingPhase 2
Testing TQ05105 for intermediate/high-risk myelofibrosis
This trial tests a new drug called TQ05105 to see if it can help people with a blood-marrow disease called myelofibrosis. The study focuses on patients whose condition is moderate to severe and measures how well the drug works and how safe it is.
Hefei, AnhuiAges 18 years+ - NCT07548697RecruitingEarly Phase 1
Safety study of CT1182 for relapsed B-cell lymphoma
This early-stage trial tests a new drug called CT1182 for B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatment. The study will measure how safe the drug is, how well it works, and how your body processes it.
Wuhan, HubeiAges 18–75 - NCT07540897RecruitingPhase 3
Testing ALKS 2680 for narcolepsy type 1
This study tests whether a new medication called ALKS 2680 can help people with narcolepsy type 1 stay more awake and alert during the day. Narcolepsy type 1 is a neurological condition where people fall asleep unexpectedly and may experience sudden muscle weakness.
Brandon, FloridaAges 18–70 - NCT06734832RecruitingPhase 3
Vaccine trial for hand, foot, and mouth disease
This trial tests a new two-in-one vaccine to protect children against hand, foot, and mouth disease caused by two common viruses (EV71 and CA16). It is for healthy kids ages 6 months to 5 years and will check if the vaccine is safe and works well.
Hefei, AnhuiAges 6 months–5.9 years - NCT07519109RecruitingPhase 1
SYH9089 for pain after abdominal surgery
This study tests an injected medicine (SYH9089) to see if it safely controls pain after abdominal surgery. It may help you recover with less discomfort.
Changsha, HunanAges 18–75 - NCT07521852RecruitingPhase 2
New drug combination with immunotherapy for liver cancer
This trial tests a new drug called CVM-1118 combined with an immunotherapy drug (sintilimab) and a procedure called TACE (a catheter-based treatment that delivers medicine directly to tumors) in people with hepatocellular carcinoma (liver cancer) that cannot be cured by surgery. The goal is to see if this combination is effective and safe.
Fuzhou, FujianAges 18 years+ - NCT07486934RecruitingPhase 3
Study of DYNE-101 for Myotonic Dystrophy Type 1
This trial tests an experimental drug called DYNE-101 to see if it can help people with myotonic dystrophy type 1 (DM1). The study aims to improve muscle function and daily life. It is for adults who can walk and stand up from a chair without help.
La Jolla, CaliforniaAges 16 years+ - NCT07478744RecruitingPhase 2
Study for generalized anxiety disorder with SYT-510
This trial tests a new medicine called SYT-510 for adults with generalized anxiety disorder who are not currently taking medication. It aims to see if the drug reduces anxiety and is safe.
LondonAges 18–55 - NCT07467707RecruitingPhase 3
Chikungunya vaccine trial for teens and adults
This trial tests an experimental chikungunya vaccine (made from a virus-like particle) to see if it prevents the disease. It is for healthy teens and adults who have not had chikungunya before.
Cebu City, CebuAges 12 years+
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,733 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.